BIT Capital GmbH Grows Stock Position in BioNTech SE (NASDAQ:BNTX)

BIT Capital GmbH boosted its holdings in BioNTech SE (NASDAQ:BNTX) by 13.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,480 shares of the company’s stock after buying an additional 2,370 shares during the period. BIT Capital GmbH’s holdings in BioNTech were worth $2,220,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its position in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the period. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. Generali Investments CEE investicni spolecnost a.s. purchased a new stake in shares of BioNTech during the 4th quarter valued at $137,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of BioNTech during the 4th quarter worth $168,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 1.2 %

NASDAQ:BNTX opened at $95.90 on Thursday. The stock has a market cap of $23.01 billion, a price-to-earnings ratio of -45.67 and a beta of 0.30. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The business’s 50-day simple moving average is $112.10 and its 200 day simple moving average is $113.72.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the company posted $1.90 EPS. BioNTech’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts predict that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BNTX shares. Wells Fargo & Company initiated coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target for the company. Citigroup assumed coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a “buy” rating and a $145.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Morgan Stanley dropped their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Finally, BMO Capital Markets lifted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.